Trial Profile
A Randomized, Open-label, Single-Dose, 2-Treatment, 2-Way, 2-Period Crossover Study to Assess the Safety and the Pharmacokinetic Characteristics of Lodivikar Tab. 5/40 mg in Healthy Adult Male Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 18 Sep 2019
Price :
$35
*
At a glance
- Drugs Olmesartan medoxomil/amlodipine (Primary)
- Indications Hypertension
- Focus Pharmacokinetics
- Sponsors Hanlim Pharmaceutical
- 15 Jun 2017 Results published in the Clinical Therapeutics
- 15 Dec 2016 New trial record